Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?

•Pancreatic Cancer is increasingly viewed as a systemic disease, with chemotherapy a key component of treatment.•Known racial disparities exist in the outcomes from pancreatic cancer, often linked to socioeconomic variables.•In patients undergoing surgery and systemic therapy, White patients were found to have improved survival compared to Black.•Differences in tumour biology may account for these differences, but controlled prospective studies are needed.